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Text: Background and objective: Iron accumulation within basal ganglia and related structures has 
been described in multiple sclerosis (MS). In early stages of the disease iron deposition may be 
associated with the progression of the disease. The aim of this longitudinal study is to assess the 
influence of iron deposit in basal ganglia and related structures in patients presenting with a 
clinically isolated syndrome (CIS).
Materials and methods: 45 patients diagnosed of CIS (27 women; median age, 34 years; EDSS 
range, [0, 5]) with a clinical follow-up of at least 3 years, underwent two 3.0 T brain MRI scan, 
baseline and 1-year follow-up, that include a T1 magnetization prepared rapid acquisition gradient 
echo (MPRAGE), and a dual-echo susceptibility weighted (SW) sequences. Thalamus, caudate, 
putamen, pallidum and accumbens area masks were obtained on MPRAGE images using FIRST 
tool of FSL package (FMRIB software library, Oxford) and registered to SW images. Iron deposits 
within these regions were obtained by R2* maps measured on magnitude SW images for baseline, 
and 1-year scans. The increment of iron between 1-year and baseline scans was also measured for 
all these regions. Conversion to MS was assessed according to McDonald criteria and new relapse 
within three years was also studied. Statistical analysis involved U Mann-Whitney test to evaluate 
differences in iron measurements between groups.
Results: We only found significant differences for the increase of iron in thalamus region between 
1-year and baseline scan when comparing the presence of a new relapse within 3 years (yes, 1.15; 
no, 0.56; p-value=0.014). With regard to the other regions, though we observed an increase of iron 
deposit for the group presenting a new relapse these did not show significant differences. Baseline 
and 1-year iron measurements did not present significant differences between those patients that 
converted to MS and those that did not in the first year.
Conclusions: The results of this longitudinal study suggest that just a reduced number of iron 
variables may be useful to discriminate CIS patients who fulfilled the criteria for establishing the 
diagnosis of MS.
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